Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
Full description
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
A participant will be placed into one of two groups: Group A: Usual Care vs. Group B: SDM Toolkit according to the randomized placement of the assigned study clinician.
Study procedures include questionnaires and option interviews with study staff.
Participation in this research study is expected to last about 2 years.
It is expected about 52 clinicians and 312 participants will take part in this research study.
The National Institute on Aging is providing funding for this research study
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Participant Inclusion Criteria:
Women aged ≥ 80 years at the time of registration
History of stage 0-III breast cancer (Of note: ductal carcinoma in situ [DCIS], pleomorphic lobular carcinoma in situ [because it is typically treated like DCIS], or invasive breast cancer of any subtype are all eligible)
No history of a recurrent breast cancer (i.e., a breast cancer that is deemed metastatic or a locoregional recurrence of a prior cancer per clinician judgement rather than a new primary breast cancer). If a person has been diagnosed with multiple distinct breast cancers over time (e.g., history of left and right breast cancer), they are eligible as long as they meet other requirements for time since surgery, etc.
Has at least one intact breast
Has had mammogram screening/surveillance within the last 24 months
-≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)
No active cancer-directed therapy other than hormonal therapy and/or CDK 4/6 inhibitor therapy
Ability and willingness to take surveys
Receiving at least some of their oncology follow-up care at a participating site
Most recent mammogram report for the potential participant did not recommend additional diagnostic work-up or close interval follow-up imaging
Participant Exclusion Criteria:
Clinician Inclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
364 participants in 2 patient groups
Loading...
Central trial contact
Rachel Freedman, MD, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal